Patients usually present with B symptoms with advanced stage III to IV disease with peripheral or abdominal lymphadenopathy. [1] Lymph node involvement is most common. Extranodal spread is less common than in the ALK-positive form. The most frequent extranodal sites are skin, liver, and lung. [1] Of note, there is a primary cutaneous anaplastic large cell lymphoma that may be difficult to distinguish clinically from secondary skin involvement by systemic ALCL. [16]  Clinical presentation includes solitary or localized skin lesions such as tumors, nodules, or papules. [6]

The most critical stain for diagnosing ALK(-) ALCL is the diffuse and strong positivity for CD30. It is usually membranous and in the Golgi staining region, although diffuse cytoplasmic positivity is also common. Usually, at least one T-cell antigen is expressed such as CD2, CD3, CD5, and CD7. If there is a loss of T-cell antigens (“null-cell phenotype”), CD43 may be useful to establish the lesion as hematolymphoid. CD45 is not reliably positive. CD4 is typically positive, and CD8 is negative. Many express the cytotoxic molecules TIA-1, Granzyme-B, perforin, and clusterin. Vimentin may be positive and should not be interpreted as evidence of mesenchymal origin. EBV-latent membrane protein type 1 and EBER in situ hybridization are negative in ALK(-) ALCL [17]. Markers of B-cell lineage are absent, including PAX5, CD19, CD20, and CD79a.   However, MUM1, which is typically seen on B-cell and plasma cell neoplasms, is frequently expressed [18]. By definition, ALK immunohistochemistry is negative, which reflects the lack of an ALK rearrangement. Fluorescent in-situ hybridization (FISH) studies for ALK rearrangement are not necessary if immunohistochemistry is negative.

Until recently, the genetics of ALK(-) ALCL has been unknown. Recent studies have shown that 30% of ALK(-) ALCL have chromosomal rearrangements of DUSP22 and 8% have chromosomal rearrangements of TP63 [19]. These rearrangements are mutually exclusive of each other and are absent in ALK-positive ALCLs [5]. Furthermore, DUSP22 rearranged cases have favorable outcomes similar to ALK-positive ALCL. By contrast, TP63 rearranged ALCLs have worse outcomes. Five-year overall survival rates for DUSP22 rearranged ALCL were 90%, compared to 85% for ALK-positive ALCL. The rate for TP63 rearranged ALCL was 17%, and the rate for cases lacking all three genetic markers (ALK, DUSP22, and TP63) was 42% [19]. Testing for DUSP22 and TP63 rearrangements is not widely available at this time.

Gene expression profiling is also useful as a diagnostic tool to distinguish peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and cutaneous ALCL from ALK(-) ALCL. IRF4 (interferon regulatory factor-4) translocations are suggestive of cutaneous ALCL over other CD30 positive lymphoproliferative disorders. Systemic ALCL tends to have other IRF4 abnormalities but no translocations [1][20]. A recent study has defined a set of three genes (TNFRSF8, BATF3, and TMOD1) whose co-expression could potentially separate ALK(-) ALCL from peripheral T-cell lymphomas. The study found that when these three genes are expressed, ALK(-), ALCL could be distinguished from PTCL-NOS with an overall accuracy near 97% in unrelated groups of patients [21].

There is no known optimal therapy for ALK(-) ALCL due to disease rarity, heterogeneity of clinical presentation, and lack of randomized trials focused on this lymphoma. ALK(-) ALCL is usually analyzed with other T-cell lymphomas, including most peripheral T-cell lymphoma categories, so there are few retrospective studies focused solely on adult patients with ALK(-) ALCL. Chemotherapy for peripheral T-cell lymphomas is derived from experiences in treating aggressive B-cell lymphomas. ALK(-) ALCL is generally responsive to doxorubicin-based chemotherapy regimens, but relapses are frequent [1]. The standard first-line treatment for systemic ALCL is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). The standard therapy for patients with relapsed or refractory disease has not been established. Newer approaches include targeted therapy such as Brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate used for relapsed/refractory systemic ALCL [1][22]. A recent study reported a case of relapsed systemic ALK-negative ALCL that was similar to the primary disease except for the loss of CD30 expression immunohistochemically after BV therapy [22].

Biopsies of ALK(-) ALCL are challenging and require exclusion of other malignancies. ALK(-) ALCL can mimic other non-hematologic malignancies such as sarcomas, carcinomas, germ cell tumors, and melanomas both cytologically and histologically. This is especially true in lesions characterized predominately by anaplasia and pleomorphism when “hallmark cells” with horseshoe-shaped or wreath-like nuclei are difficult to appreciate [20]. Besides nuclear morphology, the architectural pattern of ALCL can mimic other non-hematologic malignancies as both ALK(-) ALCL, and metastatic carcinoma tend to invade lymph node sinuses. Special care should be taken in small specimens, especially the fine-needle aspiration (FNA) specimen.  There have been several case reports describing cytomorphologic features of ALCL mimicking soft tissue sarcomas on FNA biopsy specimens [23][24].

In the absence of clear histologic clues to the cell of origin, a typical initial immunohistochemical workup will often attempt to broadly classify the lesion as carcinoma (with a pancytokeratin cocktail), melanoma (with S100 or more specific markers), or lymphoma (with CD45). If the initial round of stains is either negative or only positive for CD45, CD30 should be performed as part of a more directed panel. To differentiate between ALCL and metastatic carcinoma, epithelial membrane antigen (EMA) staining should be avoided as it is more common in ALK-positive ALCL (83%) than in ALK(-) ALCL (43%) [20][25].  Instead, cytokeratins should be preferred as markers of epithelial differentiation, which have only rarely been reported in ALCL [26].   

Detection of diffuse and strong CD30 expression should raise a high suspicion of ALCL. Many other lymphoid neoplasms may be variably CD30 positive: classical Hodgkin lymphoma, diffuse large B-cell lymphoma, PTCL-NOS, enteropathy associated T-cell lymphoma (type 2), extranodal NK/T-cell lymphoma, nasal type, and transformed mycosis fungoides. Non-neoplastic immunoblast proliferations show variable CD30 positivity as well. Other tumors such as embryonal carcinoma are typically CD30 positive but are excluded by keratin expression.  Although there are many entities which may express CD30, they typically not have the diffuse and strong pattern that is seen in ALCL.

Differentiating ALK(-) ALCL from other CD30 positive T cell lymphoproliferative disorders can be challenging because of shared morphologic and immunophenotypical features. This pattern of CD30 expression is important to distinguish ALK(-) ALCL from other peripheral T cell lymphomas that have variable CD30 expression. An exception to this rule is the variable CD30 staining seen in the small-cell variant of ALK-positive ALCL [27]. ALK-positive ALCL is easily distinguished from ALK(-) ALCL by the presence of ALK staining by immunohistochemistry. The diagnosis of primary cutaneous ALCL requires clinicopathologic correlation to rule out secondary involvement systemic ALCL.

IHC plays a relevant role in distinguishing ALK(-) ALCL from classical Hodgkin lymphoma (CHL). This is especially useful if there is a high concentration of malignant cells in a case of CHL, as is seen in the syncytial variant. CHL is recognizable for B-cell marker expression and dim PAX-5 positivity, CD15, and occasionally EBER. MUM1 does not distinguish between ALCL and CHL. Only exceptional cases of ALCL express PAX-5 [1][28]. It is important to recognize that CHL will frequently express T-cell antigens.  CD4 and CD2 are seen in more than half of cases; CD3, CD5, and/or CD7 are seen in approximately one-third of cases [29]]. Cytotoxic T-cell markers, such as TIA-1 are typically positive in ALK(-) ALCL and negative in CHL.

There is no specific immunophenotypic or genetic features to define ALK(-) ALCL; the immunophenotype of primary cutaneous and systemic ALK(-) ALCL are indistinguishable [8]. Both have strong expression of CD30 with variable expression of T-cell antigens (CD2, CD3, and CD5). Both often express CD4 and cytotoxic proteins. Primary cutaneous ALCL expresses cutaneous lymphocytes antigen more frequently and EMA less frequently than ALK(-) ALCL, but these markers are not specific enough to distinguish these entities by phenotype alone [8][25]. At present, both entities share recurrent genetic abnormalities, of which the most common are DUSP22 rearrangements which occur in about 28% of cases of primary cutaneous ALCL and 30% of systemic ALK(-) ALCL which may secondarily involve the skin. Clinical staging remains necessary to distinguish DUSP22 rearranged cases of primary cutaneous ALCL from systemic ALK(-) ALCL with DUSP22 rearrangement and skin involvement. ALK-positive ALCL is molecularly characterized and can be readily diagnosed with the highly specific combination of CD30 and ALK positivity. 

Recent studies have shown differences in overall prognosis among patients with ALK(-) ALCL based on the presence of different chromosomal rearrangements. For instance, 30% of patients with ALK(-) ALCL have been found to have the DUSP22 rearrangement with a 90% five-year overall survival rate, which is similar to that of ALK-positive ALCL. 8% of ALK(-) ALCL patients have the TP63 rearrangement with a far worse five-year overall survival rate of 17%. Finally, the 5-year overall survival rate of patients lacking ALK, DUSP22, or TP63 rearrangement is 42% [4][19]. In comparison to other CD30 positive T-cell lymphomas, patients with ALK(-) ALCL have a superior 5-year overall survival rate (49%) in comparison to PTCL-NOS (32%), but ALK-positive ALCL still has the better prognosis (70%). However, the favorable prognosis may be due to a younger age of presentation as one study found no outcome difference when the analysis was limited to ALCL patients 40 years of age and older. In comparison, primary cutaneous ALCL seems to have a more indolent course because it has a favorable 5-year overall survival rate (90%), but with a propensity to relapse with a 5-year failure-free survival of 55% [25].

ALK(-) ALCL is a T-cell lymphoma characterized by large, anaplastic lymphoid cells with uniform, strong expression of CD30 but a lack of ALK protein expression. It tends to grow cohesively and invade lymph node sinuses. It also has a vast morphologic spectrum and may mimic other entities featuring pleomorphic and anaplastic cells with wreath-like or horseshoe-shaped nuclei. Morphology and immunohistochemistry are the mainstays used to distinguish this entity from other ALK-positive ALCL, CD30 positive T-cell lymphomas, and classical Hodgkin lymphoma as well as other non-hematologic malignancies such as carcinomas, sarcomas, and melanomas. ALK(-) ALCL has a poorer prognosis than ALK-positive ALCL, but it has a better prognosis than peripheral T-cell Lymphoma, NOS. Molecular studies have identified DUSP22 rearranged ALK(-) ALCL as having a prognosis similar to ALK-positive ALCL. Regarding treatment, ALK(-) ALCL is generally responsive to doxorubicin-containing chemotherapy (CHOP regimen), but relapses are frequent. CD30 is a newer therapeutic target and brentuximab vedotin (anti CD30) has been used for relapsed/refractory systemic ALCL.

When healthcare professionals see patients with symptoms suggestive of lymphoma, prompt referral to an oncologist/hematologist is recommended. These patients may present with solitary or localized skin lesions such as tumors, nodules. Prior to undertaking treatment, the type of lymphoma needs to be ascertained.  ALK(-) ALCL is a T-cell lymphoma characterized by large, anaplastic lymphoid cells with uniform, strong expression of CD30 but a lack of ALK protein expression. It tends to grow cohesively and invade lymph node sinuses. ALK(-) ALCL has a poorer prognosis than ALK-positive ALCL, but it has a better prognosis than peripheral T-cell Lymphoma, NOS. Molecular studies have identified DUSP22 rearranged ALK(-) ALCL as having a prognosis similar to ALK-positive ALCL. Regarding treatment, ALK(-) ALCL is generally responsive to doxorubicin-containing chemotherapy (CHOP regimen), but relapses are frequent. CD30 is a newer therapeutic target and brentuximab vedotin (anti CD30) has been used for relapsed/refractory systemic ALCL.